HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

IMMU-110

drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74 monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody ratio of approximately 8:1 (mol/mol); the excellent safety and efficacy profile of IMMU-110 supports clinical testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies
Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Stein, Rhona: 1 article (07/2005)
2. Horak, Ivan D: 1 article (07/2005)
3. Cardillo, Thomas M: 1 article (07/2005)
4. Goldenberg, David M: 1 article (07/2005)
5. Griffiths, Gary L: 1 article (07/2005)
6. Hansen, Hans J: 1 article (07/2005)
7. Qu, Zhengxing: 1 article (07/2005)
8. Govindan, Serengulam V: 1 article (07/2005)
9. Sapra, Puja: 1 article (07/2005)
10. Pickett, Jennifer: 1 article (07/2005)

Related Diseases

1. Multiple Myeloma
2. Neoplasms (Cancer)

Related Drugs and Biologics

1. Doxorubicin (Adriamycin)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)